Kuriki O, Ono Y, Katoh N, Sahashi M, Kinukawa T, Matsuura O, Ohshima S
Shakaihoken Chukyo Hospital.
Nihon Hinyokika Gakkai Zasshi. 1995 Apr;86(4):919-26. doi: 10.5980/jpnjurol1989.86.919.
Between 1984 and 1992, 131 patients with bladder cancer underwent radical cystectomy and pelvic lymph node dissection with urinary diversion. There were 110 male and 21 female patients, aged between 35 and 86 with a mean of 64 years. The follow-up period ranged from 1 month to 113 months, with a median of 34 months. The five-year survival estimated by the Kaplan-Meier method was 66.9% over all 131 patients. The five-year survival rates were 83.3% for stage pTis patients, 66.7% for stage pTa, 97.0% for pT1, 70.7% for pT2, 47.9% for pT3a, 26.2% for pT3b, and four-year survival was 25% for pT4 disease. Under the grading system, the five-year survival was 80.0% for cases of grade 2 disease and 63.6% for grade 3. There were two grade 1 patients who died of other diseases 15 and 16 months after surgery. Of all 131 patients, 22 (16.8%) had lymph node involvement. The five-year survival was 34.5% for patients with positive lymph nodes in comparison with 73.8% for those without lymph node involvement. The frequency of lymph node involvement was 26.1% in the non TCC group and 14.8% in the TCC group including 23.7% of the grade 3 and 4.3% of the grade 2 cases. Pathologically, the patients with higher stages had a higher frequency of lymph node involvement, and there was a significant difference in the frequency between pT3a (14.3%) and pT3b (47.8%) disease. The five-year survival of patients with positive lymph nodes was 40.0% for pN1, 32.1% for pN2 disease.(ABSTRACT TRUNCATED AT 250 WORDS)
1984年至1992年间,131例膀胱癌患者接受了根治性膀胱切除术、盆腔淋巴结清扫术及尿流改道术。其中男性110例,女性21例,年龄在35岁至86岁之间,平均年龄64岁。随访时间为1个月至113个月,中位数为34个月。采用Kaplan-Meier法估计,131例患者的五年生存率为66.9%。pTis期患者的五年生存率为83.3%,pTa期为66.7%,pT1期为97.0%,pT2期为70.7%,pT3a期为47.9%,pT3b期为26.2%,pT4期疾病的四年生存率为25%。在分级系统下,2级疾病患者的五年生存率为80.0%,3级为63.6%。有2例1级患者在术后15个月和16个月死于其他疾病。131例患者中,22例(16.8%)有淋巴结受累。淋巴结阳性患者的五年生存率为34.5%,无淋巴结受累患者为73.8%。非移行细胞癌组淋巴结受累频率为26.1%,移行细胞癌组为14.8%,其中3级为23.7%,2级为4.3%。病理上,分期较高的患者淋巴结受累频率较高,pT3a期(14.3%)和pT3b期(47.8%)疾病的淋巴结受累频率有显著差异。pN1期淋巴结阳性患者的五年生存率为40.0%,pN2期为32.1%。(摘要截短至250字)